Tumor mutational burden as a predictor of immunotherapy response: Is more always better?

journal contribution

posted on 2024-06-13, 14:16 authored by JH Strickler, BA Hanks, M Khasraw

Tumor mutational burden as a predictor of immunotherapy response: Is more always better?

History

Journal

Clinical Cancer Research

Volume

27

Pagination

1236-1241

Location

United States

Open access

Yes

Link to full text

https://aacrjournals.org/clincancerres/article-pdf/27/5/1236/2067461/1236.pdf

ISSN

1078-0432

eISSN

1557-3265

Language

en

Author URL

https://www.ncbi.nlm.nih.gov/pubmed/33199494

Publication classification

C1 Refereed article in a scholarly journal

Issue

5

Publisher

American Association for Cancer Research (AACR)

Usage metrics

Categories

Oncology and carcinogenesis not elsewhere classified

Keywords

Antineoplastic Agents, Immunological Biomarkers, Tumor Humans Immunotherapy Mutation Neoplasms Prognosis Survival Rate Tumor Burden 3211 Oncology and carcinogenesis 3204 Immunology

Licence

All Rights Reserved

Exports